Related references
Note: Only part of the references are listed.Prospective phenotypic screening for DPD deficiency prior to 5-FU administration: Decrease in toxicity, not in efficacy
C. Mercier et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase
A. Lazar et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2008)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences
Keiko Maekawa et al.
JOURNAL OF HUMAN GENETICS (2007)
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity
Nicolas Magne et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Chemotherapy of advanced gastric cancer
Fernando Rivera et al.
CANCER TREATMENT REVIEWS (2007)
FRA1E common fragile site breaks map within a 370 kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD)
Fabiola Hormozian et al.
CANCER LETTERS (2007)
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin
Andre B. P. van Kuilenburg et al.
EUROPEAN JOURNAL OF CANCER (2007)
Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference
S. Cinieri et al.
ANNALS OF ONCOLOGY (2007)
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU - Results from genotyping study on 75 gastric carcinoma and colon carcinoma patients
Hong Zhang et al.
MEDICAL ONCOLOGY (2007)
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients
Zhi Wei Zhou et al.
CHEMOTHERAPY (2007)
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
Alain Morel et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy
Joseph Ciccolini et al.
THERAPEUTIC DRUG MONITORING (2006)
Pharmacogenetics of capecitabine in advanced breast cancer patients
Rmy Largillier et al.
CLINICAL CANCER RESEARCH (2006)
Review of capecitabine as oral treatment of gastric, gastroesophageal, and Esophageal cancers
Jaffer Ajani
CANCER (2006)
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals
K Seck et al.
CLINICAL CANCER RESEARCH (2005)
Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations
K Ogura et al.
CLINICAL CANCER RESEARCH (2005)
Haploview: analysis and visualization of LD and haplotype maps
JC Barrett et al.
BIOINFORMATICS (2005)
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test
LK Mattison et al.
CLINICAL CANCER RESEARCH (2004)
Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients
N Salgueiro et al.
GENETICS IN MEDICINE (2004)
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
ABP van Kuilenburg
EUROPEAN JOURNAL OF CANCER (2004)
Detailed Analysis of Five Mutations in Dihydropyrimidine Dehydrogenase Detected in Cancer Patients With 5-fluorouracil-related Side Effects
Eva Gross et al.
HUMAN MUTATION (2003)
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
W Scheithauer et al.
ANNALS OF ONCOLOGY (2003)
High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
ABP van Kuilenburg et al.
PHARMACOGENETICS (2002)
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure
ABP van Kuilenburg et al.
BIOCHEMICAL JOURNAL (2002)
A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms
LK Mattison et al.
PHARMACOGENETICS (2002)
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
A Di Paolo et al.
ANNALS OF ONCOLOGY (2001)
Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil
D Dobritzsch et al.
EMBO JOURNAL (2001)
Known variant DPYD alleles do not explain DPD deficiency in cancer patients
ESR Collie-Duguid et al.
PHARMACOGENETICS (2000)
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil
RB Diasio et al.
PHARMACOLOGY (2000)
Share Paper
